NAPHCON A OTC
Generic Name and Formulations:
Naphazoline HCl 0.025%, pheniramine maleate 0.3%; oph. soln; contains benzalkonium chloride.
Alcon Laboratories, Inc.
Indications for NAPHCON A:
Ocular redness and itching.
Adults and Children:
<6yrs: not recommended. ≥6yrs: 1–2 drops up to 4 times daily.
Avoid prolonged use. Narrow-angle glaucoma. Hypertension. Cardiovascular disease. Urinary hesitancy. Reevaluate if eye pain, irritation, or visual changes worsen or persist beyond 72hrs. Pregnancy. Nursing mothers.
Vasoconstrictor + antihistamine.
Avoid MAOIs. Remove soft contact lenses when instilling; may re-insert afterwards.
Mydriasis, increased IOP, local irritation, sensitization.
Clinical Pain Advisor Articles
- Virtual Reality May Effectively Reduce Sensory, Affective, and Cognitive Pain During Labor
- Suprazygomatic Sphenopalatine Ganglion Block May Quickly Relieve Status Migrainosus Pain
- Reducing Mortality After Overdose: Is Treatment for Opioid Use Disorder Effective?
- A Physician's Guide to Incorporating Patient Spirituality in Practice
- Low Literacy Self-Management Program for Chronic Pain May Be Effective
- Neuropathic Pain Medications
- Higher Buprenorphine Dose May Not Increase Severity of Neonatal Abstinence Syndrome
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Ketamine Infusions May Be Effective for Refractory Headache
- Physical, Psychosocial Activity May Be Protective Against Development of Chronic Pain in Older Adults
- FDA Approves Minimally-Invasive, Non-Drug Therapy for Pain Management
- Chronic Migraine and Medication Overuse Headache Linked to Stress
- Set of Personality Traits May Predict Prescription Drug Use, Misuse in Young Adults
- The Opioid Crisis: District by District
- Opioid Administration, Prescribing in the ED on the Decline in Recent Years